Pages that link to "Q40226384"
Jump to navigation
Jump to search
The following pages link to Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade (Q40226384):
Displaying 50 items.
- Captopril in the treatment of clinical hypertension and cardiac failure (Q28318616) (← links)
- Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy (Q33496078) (← links)
- Failure of captopril to reverse the renal crisis of scleroderma (Q33554064) (← links)
- A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma). (Q33554937) (← links)
- Mistaken identity: normotensive scleroderma renal crisis (Q33691380) (← links)
- Scleroderma renal crisis: new insights and developments (Q34305170) (← links)
- Combination therapies for systemic sclerosis (Q34309698) (← links)
- Hyponatremia in a patient with scleroderma renal crisis: a potential role of activated renin-angiotensin system (Q34318825) (← links)
- Renal involvement in systemic sclerosis (Q34333108) (← links)
- Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon (Q34747435) (← links)
- Letter from Chicago: Temples, tubes, and plastic bags (Q34760289) (← links)
- Role of renin secretion and kidney function in hypertension and attendant heart attack and stroke (Q35898763) (← links)
- Scleroderma and the kidney (Q35939760) (← links)
- Pathogenesis and treatment of Raynaud's phenomenon (Q38031566) (← links)
- Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis (Q38681754) (← links)
- Successful treatment of scleroderma renal crisis with enalapril (Q38954017) (← links)
- Scleroderma renal crisis and renal involvement in systemic sclerosis (Q38957950) (← links)
- Pathogenesis of systemic sclerosis-current concept and emerging treatments (Q39294794) (← links)
- Angiotensin converting enzyme inhibitors in Raynaud's phenomenon (Q39370948) (← links)
- Systemic scleroderma. Clinical and pathophysiologic aspects (Q39634078) (← links)
- Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy (Q40300185) (← links)
- Choosing the right ACE inhibitor. A guide to selection (Q40549836) (← links)
- Renin profiling for diagnosis, risk assessment, and treatment of hypertension (Q40792092) (← links)
- Management of systemic sclerosis: The art and science (Q40866035) (← links)
- The renin system for understanding human hypertension: evidence for blood pressure control by a bipolar vasoconstriction-volume mechanism. Prorenin as a determinant of renin secretion (Q41465055) (← links)
- Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis (Q41695601) (← links)
- Evaluation of the chronotropic property of captopril in hypertensive patients (Q42241715) (← links)
- Captopril. (Q42856312) (← links)
- Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases (Q47880572) (← links)
- Scleroderma renal crisis (Q56060966) (← links)
- CAPTOPRIL IN THE TREATMENT OF CLINICAL HYPERTENSION AND CARDIAC FAILURE (Q56337625) (← links)
- Favourable outcome of scleroderma renal crisis. (Q64994093) (← links)
- Recovery of renal function in undifferentiated connective tissue disease after treatment with angiotensin-converting enzyme inhibitors (Q68075263) (← links)
- Use of captopril as early therapy for renal scleroderma: a prospective study (Q69914602) (← links)
- Angiotensin-converting enzyme inhibitors in the treatment of hypertension (Q70196531) (← links)
- Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor mk 421 (enalapril) in captopril-intolerant patients (Q70221883) (← links)
- Membranous glomerulopathy associated with captopril therapy (Q70249025) (← links)
- Reversal of Scleroderma Renal Crisis for More Than Two Years in a Patient Treated with Captopril (Q70261697) (← links)
- [Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin in scleroderma] (Q70278049) (← links)
- Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril (Q70390421) (← links)
- Scleroderma renal crisis (Q71788221) (← links)
- Captopril-associated agranulocytosis (Q72418360) (← links)
- Captopril lowers urinary kallikrein in hypertensive patients (Q72418365) (← links)
- Pharmacologic agents used in the management of acute renal failure (Q72450409) (← links)
- Inhibitors of angiotensin I converting enzyme for treating hypertension (Q72622046) (← links)
- Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors (Q72649396) (← links)
- Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril (Q72889402) (← links)
- Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients (Q72925583) (← links)
- Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril (Q72962850) (← links)
- Disease severity as a predictor of outcome in scleroderma (Q77601190) (← links)